Overview

Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass

Status:
Unknown status

Trial end date:
2012-07-01

Target enrollment:

Participant gender:

Summary

This study is being conducted to evaluate the effect treatment has on serum P1NP levels, a biomarker of bone formation in postmenopausal women with low bone mass.

Phase:

Phase 2

Details

Lead Sponsor:

Azelon Pharmaceuticals

Treatments:

Teriparatide